Moderna Inc has said its Covid-19 vaccine has generated a strong immune response and is generally well-tolerated in children aged six to 11 years, citing interim data from a study.
According to Reuters, the company said it planned to submit the data to US, European and other regulators soon.
Moderna said the data showed two 50 microgram doses of the vaccine, half the strength of the doses used in the vaccine given to adults, generated virus-neutralising antibodies in children.
The majority of side effects were mild or moderate in severity, the company said.
